fensolvi

Fensolvi is a branded, long-acting injectable formulation of leuprolide acetate, a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH). It acts as a GnRH agonist and is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). Fensolvi utilizes an innovative in-situ polymeric gel delivery system that allows for sustained release over six months following subcutaneous injection. By continuously stimulating pituitary GnRH receptors, it initially increases and then suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to decreased production of sex steroids from the gonads. This mechanism halts or reverses premature pubertal development in affected children. The drug was developed by Tolmar Pharmaceuticals[3][4][5][10].

Brand names

Fensolvi

Other names

leuprolide acetate injectable suspensionleuprolide acetate (Fensolvi formulation)